Discovery of insulin in the early 1900s initiated the research and development to improve
the means of therapeutic protein delivery in patients. In the past decade, great emphasis has …

The advancement of delivery tools for therapeutic agents has brought several novel
formulations with increased drug loading, sustained release, targeted delivery, and …

Lamellar liposome technology has been used for several decades to produce sustained-
release drug formulations for parenteral administration. Multivesicular liposomes are …

The mechanism of drug release from complex dosage forms, such as multivesicular
liposomes (MVLs), is complex and oftentimes sensitive to the release environment. This …

Abstract Interleukin 2 (IL2) is the first approved immunotherapeutic agent in cancer
treatment. However, high‐dose IL2 administrated through intratumoral injection still spreads …

Recent studies regarding mucosal drug delivery indicate that nanosystems with surface-
available polyethylene glycol (PEG) are able to penetrate mucus barrier, assure closer …

Multivesicular vesicles, ie vesicles containing internal, non‐concentrically arranged smaller
vesicles, are artificial, polymolecular compartment systems, which can be prepared from …

The advent of biopharmaceuticals in modern medicine brought enormous benefits to the
treatment of numerous human diseases and improved the well-being of many people …

Drug development is a key point in the research of new therapeutic treatments for increasing
maximum drug loading and prolonged drug effect. Encapsulation of drugs into multivesicular …

The combination of nucleic acid-based Toll-like receptor (TLR)-3 or TLR9 agonists and
cationic liposomes constitutes an effective vaccine adjuvant approach for eliciting CD8+ T …